Literature DB >> 7662454

Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.

S H Thomas1, P D Higham, K Hartigan-Go, F Kamali, P Wood, R W Campbell, G A Ford.   

Abstract

OBJECTIVE: Terodiline, an antimuscarinic and calcium antagonist drug, was used to treat detrusor instability but was withdrawn in 1991 after provoking serious ventricular arrhythmias associated with increases in the corrected QT interval (QTc). This research was performed to relate drug induced electrocardiographic changes in asymptomatic recipients to plasma concentrations of the R(+) and S(-) terodiline enantiomers.
SETTING: Urological and geriatric clinics and wards.
SUBJECTS: Asymptomatic patients taking terodiline in stable dose.
METHODS: Electrocardiograms (50 mm/s) were collected from patients while they were taking terodiline and compared with ECGs obtained before or after terodiline. QT interval, heart rate corrected QT interval (QTc), and QT dispersion (QTd) were measured. Drug induced electrocardiographic changes were related to plasma concentrations of R(+) and S(-) terodiline.
RESULTS: During terodiline treatment mean QTc and QTd were prolonged (491(43) and 84 (35) ms 1/2) compared with measurements made off therapy (443 (33) and 42 (17) ms 1/2, paired t tests, P < 0.002 and P < 0.01 respectively) in the 12 patients in sinus rhythm. The mean (95% confidence interval) drug induced increases were 48 (23 to 74) ms 1/2 for QTc and 42 (13 to 70) ms 1/2 for QTd. These increases correlated with total plasma terodiline (QTc: r = 0.77, P < 0.006, QTd: r = 0.68, P < 0.025) and with plasma concentrations of both terodiline enantiomers.
CONCLUSIONS: Terodiline increases QTc and QTd in a concentration dependent manner. It is not clear whether this is a stereoselective effect and, if so, which enantiomer is responsible. The results suggest that drug induced torsade de pointes is a type A (concentration dependent) adverse drug reaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662454      PMCID: PMC483946          DOI: 10.1136/hrt.74.1.53

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  26 in total

1.  Incessant atrial tachycardia accelerated by pregnancy.

Authors:  J C Doig; J M McComb; D S Reid
Journal:  Br Heart J       Date:  1992-03

2.  Ventricular arrhythmias caused by prenylamine.

Authors:  R Puritz; M A Henderson; S N Baker; D A Chamberlain
Journal:  Br Med J       Date:  1977-09-03

3.  Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients.

Authors:  B Hallén; A Magnusson; S Bogentoft; P Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Diseases and drugs causing prolongation of the QT interval.

Authors:  M Laakso; A Aberg; J Savola; P J Pentikäinen; K Pyörälä
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

5.  Torsades de pointes ventricular tachycardia and terodiline.

Authors:  M J Connolly; P S Astridge; E G White; C A Morley; J C Cowan
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

6.  Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval.

Authors:  D A Stewart; J Taylor; S Ghosh; G J Macphee; I Abdullah; J M McLenachan; D J Stott
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Comparison of the calcium-antagonistic effects of terodiline, nifedipine and verapamil.

Authors:  C Larsson-Backström; E Arrhenius; K Sagge
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-07

Review 8.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

9.  Biotransformation of terodiline. III. Opposed stereoselectivity in the benzylic and aromatic hydroxylations in rat liver microsomes.

Authors:  B Lindeke; O Ericsson; A Jönsson; B Noren; S Strömberg; B Vangbo
Journal:  Xenobiotica       Date:  1987-11       Impact factor: 1.908

10.  Clinical pharmacology of terodiline.

Authors:  K E Andersson
Journal:  Scand J Urol Nephrol Suppl       Date:  1984
View more
  8 in total

1.  Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.

Authors:  S E Jones; L M Shuba; P Zhabyeyev; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

Authors:  G A Ford; S M Wood; A K Daly
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

3.  Block and modified gating of cardiac calcium channel currents by terodiline.

Authors:  T Ogura; S Jones; L M Shuba; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Electrophysiological profile of propiverine--relationship to cardiac risk.

Authors:  Torsten Christ; Erich Wettwer; Melinda Wuest; Manfred Braeter; Frank Donath; Pascal Champeroux; Serge Richard; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

Review 5.  The Q-T interval and antimuscarinic drugs.

Authors:  Roger Dmochowski; David R Staskin
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

Review 6.  Drug-induced cardiac arrhythmias: incidence, prevention and management.

Authors:  J C Doig
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.228

7.  Action Potential Recording and Pro-arrhythmia Risk Analysis in Human Ventricular Trabeculae.

Authors:  Yusheng Qu; Guy Page; Najah Abi-Gerges; Paul E Miller; Andre Ghetti; Hugo M Vargas
Journal:  Front Physiol       Date:  2018-01-05       Impact factor: 4.566

Review 8.  Toward a broader view of mechanisms of drug cardiotoxicity.

Authors:  Polina Mamoshina; Blanca Rodriguez; Alfonso Bueno-Orovio
Journal:  Cell Rep Med       Date:  2021-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.